Abstract
The COVID-19 pandemic is an ongoing global challenge for public health systems. Rapid and early identification of infection is critical in preventing widespread COVID-19 infection by presymptomatic and asymptomatic individuals, especially in the community and in-home settings. I will introduce an ultrasensitive and low-cost telemedicine platform, the SARS-CoV-2 RapidPlex, based on target-specific immunoassays built off laser-engraved graphene for rapid and remote assessment of COVID-19 biomarkers (i.e., nucleocapsid protein, anti-spike protein IgG and IgM, and C-reactive protein). Multiplex sensing of these targets provides information on three key aspects of COVID-19 disease: viral infection, immune response, and disease severity. We successfully evaluated the applicability of our SARS-CoV-2 RapidPlex platform with COVID-19-positive and COVID-19-negative blood and saliva samples. Based on this pilot study, our multiplexed immunosensor platform may allow for high-frequency at-home testing for COVID-19 telemedicine diagnosis and monitoring. Figure 1
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
